Life Science Today
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.
Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
The Niche Episode 040 – Janssen, Fujifilm, Agiliti + Northfield, and Aktis Oncology
A new MS therapeutic, Fujifilm picks CDMO facility site, consolidation in medical services, and a new oncology startup.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/Niche-040-1
https://tinyurl.com/Niche-040-2
https://tinyurl.com/Niche-040-3
https://tinyurl.com/Niche-040-4
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 039 – Kintor, AVEO, Takeda + Maverick, AgomAb
92% reduction in COVID mortality, AVEO gets FDA approval, Takeda acquires Maverick and targets emerging markets, and AgomAb raises $74M Series B for regenerative medicine.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/Niche-039-1
https://tinyurl.com/Niche-039-2
https://tinyurl.com/Niche-039-3
https://tinyurl.com/Niche-039-4
https://tinyurl.com/Niche-039-5
https://tinyurl.com/Niche-039-6
https://tinyurl.com/Niche-039-7
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 038 – Amgen, Five Prime, KemPharm, Colfax
Amgen nabs Five Prime Therapeutics in $1.9B deal, KemPharm ligates their way out of debt with ADHD, three failed COVID19 pipelines, and Colfax follows 2019 merger with corporate split.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/niche-038-1
https://tinyurl.com/niche-038-2
https://tinyurl.com/niche-038-3
https://tinyurl.com/niche-038-4
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 037 – (Bonus) Interview with Dr. Mitrani, CSO at Organicell
I sit down with Dr. Mitrani, the Chief Scientific Officer for Organicell, a clinical stage biopharma company focused on regenerative medicine. Their leading product, Zofin is currently in early clinical trials for the treatment of COVID19. Eventually it may be a therapeutic for long haulers.
Key Talking Points
2:43 – Dr. Mitrani’s Journey to regenerative medicine
5:30 – From stem cells to nano medicine
8:12 – What is Zofin and how might it work?
9:46 – Pivoting into COVID19
11:42 – Following the science from stem cells to nano infusions
14:21 – Doing science is hard but we follow the data
19:59 – How following scientific data for years prepares you to pivot in response to crisis
25:40 – What trends have stood the test of time?
30:27 – How novel therapeutic spaces require novel approaches to product validation
34:11 – The work that is being done for COVID19 long-haulers
Sponsors
https://www.thescopemethod.com
Story References
https://organicell.com/
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 036 – PRA + ICON, J&J + FDA, Oncopeptides, Roivant, Merck
PRA acquired by Icon, Johnson & Johnson’s vaccine approved, Oncopeptides’ earns FDA approval, Roivant acquires Silicone Therapeutics, and Merck acquires Pandion.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/niche-036-1
https://tinyurl.com/niche-036-2
https://tinyurl.com/niche-036-3
https://tinyurl.com/niche-036-4
https://tinyurl.com/niche-036-5
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 035 – Eli Lilly, Charles River, Adjuvant Capital, Everlywell, Abbott
Eli Lilly bets on RIPK1, Charles River spends $875M on cell and gene therapy, Adjuvant Capital gets who’s who in backing, you can now buy an at-home COVID19 testing kit whenever you want, and Abbott does it again for the 389th time.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/niche-35-1
https://tinyurl.com/niche-35-2
https://tinyurl.com/niche-35-3
https://tinyurl.com/niche-35-4
https://tinyurl.com/niche-35-5
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
Responses